NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis $3.40 -0.07 (-2.02%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$3.33 -0.07 (-1.94%) As of 08/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arbutus Biopharma Stock (NASDAQ:ABUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arbutus Biopharma alerts:Sign Up Key Stats Today's Range$3.31▼$3.5450-Day Range$3.09▼$3.5852-Week Range$2.70▼$4.72Volume589,899 shsAverage Volume712,158 shsMarket Capitalization$651.20 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingBuy Company Overview Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Read More Arbutus Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreABUS MarketRank™: Arbutus Biopharma scored higher than 56% of companies evaluated by MarketBeat, and ranked 548th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArbutus Biopharma has received no research coverage in the past 90 days.Read more about Arbutus Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.39) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -11.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -11.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 6.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.12% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 17.2, which indicates bearish sentiment.Change versus previous monthShort interest in Arbutus Biopharma has recently decreased by 0.94%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.12% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 17.2, which indicates bearish sentiment.Change versus previous monthShort interest in Arbutus Biopharma has recently decreased by 0.94%, indicating that investor sentiment is improving. News and Social Media3.9 / 5News Sentiment1.00 News SentimentArbutus Biopharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search Interest7 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arbutus Biopharma's insider trading history. Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Stock News HeadlinesArbutus (ABUS) Q2 Revenue Surges 529%August 7 at 2:51 PM | theglobeandmail.comArbutus Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 6 at 7:30 AM | globenewswire.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Arbutus Biopharma Corporation (ABUS) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comArbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical FocusJune 25, 2025 | globenewswire.comArbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal ProgressMay 18, 2025 | msn.comArbutus Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comArbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025May 10, 2025 | msn.comSee More Headlines ABUS Stock Analysis - Frequently Asked Questions How have ABUS shares performed this year? Arbutus Biopharma's stock was trading at $3.27 at the beginning of the year. Since then, ABUS stock has increased by 4.0% and is now trading at $3.40. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Corporation (NASDAQ:ABUS) issued its quarterly earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. The biopharmaceutical company had revenue of $10.74 million for the quarter, compared to the consensus estimate of $2.21 million. Arbutus Biopharma had a negative net margin of 352.24% and a negative trailing twelve-month return on equity of 57.48%. Who are Arbutus Biopharma's major shareholders? Top institutional shareholders of Arbutus Biopharma include Aberdeen Group plc (0.51%), Bank of Montreal Can (0.31%), Wealth Management Associates Inc. (0.05%) and Assenagon Asset Management S.A. (0.02%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Cos (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA). Company Calendar Last Earnings8/06/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABUS CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees90Year Founded1992Price Target and Rating Average Price Target for Arbutus Biopharma$5.50 High Price Target$7.00 Low Price Target$5.00 Potential Upside/Downside+61.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.92 million Net Margins-1,196.64% Pretax Margin-1,195.86% Return on Equity-75.51% Return on Assets-55.81% Debt Debt-to-Equity Ratio0.04 Current Ratio6.01 Quick Ratio6.01 Sales & Book Value Annual Sales$6.40 million Price / Sales101.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book6.67Miscellaneous Outstanding Shares191,527,000Free Float152,647,000Market Cap$651.19 million OptionableOptionable Beta0.86 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ABUS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.